key: cord-0052454-ap73zrr7
authors: Fiolet, Thibault; Guihur, Anthony; Rebeaud, Mathieu E.; Mulot, Matthieu; Peiffer-Smadja, Nathan; Mahamat-Saleh, Yahya
title: Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: a systematic review and meta-analysis' – Author’s reply
date: 2020-11-06
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2020.10.031
sha: c42e5616da8de47a07d8ca5882894caae1f93260
doc_id: 52454
cord_uid: ap73zrr7

nan

To the editor 28

We would like to explain several points raised by Védrines et al. 29 30 1. We agree that Geleris et al. used a composite endpoint [1] . However, 1) intubation is a main 31 prognostic factor for death, 2) exclusion of this study from the pooled RR estimation did not 32 change our conclusion (see table S4 In our main analysis, we used this adjusted HR which takes into account indication bias (following 35 [5] . We note that this is the second 51 letter from Dr Lacout, which is quite uncommon for the same study. evidence. Védrines et al. stated that reality is complex. We agree, and we add that because reality is 72 complex, solid evidence of a favorable benefit-risk ratio is necessary. COVID-19 crisis does not make 73 the need for rigorous science obsolete: it reinforces this need. 74

As stated by the author of a recent editorial on studies evaluating tocilizumab, another putative 76 treatment for COVID-19 patients, "I plan to wait out the torrent of positive observational studies and 77 reconsider tocilizumab's use in COVID-19 if, and only if, more compelling data from randomized 78 trials emerges." Regarding hydroxychloroquine, the torrent of positive observational studies, often of 79 very low quality, has been shared but compelling data from randomized trials have already been 80 published and are univocal: hydroxychloroquine with or without azithromycin is not an effective 81 treatment for patients with COVID-19 [17] . 82

Observational Study of 85 Hydroxychloroquine in Hospitalized Patients with Covid-19

Cochrane 88 Handbook for Systematic Reviews of Interventions version 6

Outcomes of 91 hydroxychloroquine usage in United States veterans hospitalized with COVID-19

Statistical methods for analyzing right-censored length-biased data under cox 94 model

Effect of 96 hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients" -97 Author's reply

Treatment with 100 hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19

The continued dilemma about the usage of hydroxychloroquine: Respite is in 104 randomized control trials

An observational cohort study of 107 hydroxychloroquine and azithromycin for COVID-19: (Can't Get No) Satisfaction. International 108

Treatment with

Azithromycin, and Combination in Patients Hospitalized with COVID-19. 111

Effect of 114 hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 115 (COVID-19) patients: a systematic review and meta-analysis

Effect of Hydroxychloroquine in Hospitalized Patients with 118 Covid-19

WHO Solidarity trial consortium. Repurposed antiviral drugs for COVID-19-interim WHO 121 SOLIDARITY trial results n.d

Interventions for 123 treatment of COVID-19: A living systematic review with meta-analyses and trial sequential 124 analyses (The LIVING Project)

Mortality 127 outcomes with hydroxychloroquine and chloroquine in COVID-19: an international 128 collaborative meta-analysis of randomized trials

Virological and clinical 131 cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-132 analysis

Efficacy of chloroquine 134 or hydroxychloroquine in COVID-19 patients: a systematic review and meta-analysis

Time to Reassess Tocilizumab's Role in COVID-19 Pneumonia